All models are wrong, but some organoids may be useful

Benjamin E Mead^{1

2

3

4

5}, Jeffrey M Karp^{6

7

8

9}

Affiliations

¹ Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA. bemead@mit.edu.
² Institute for Medical Engineering and Science (IMES), Massachusetts Institute of Technology, Cambridge, MA, USA. bemead@mit.edu.
³ Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA. bemead@mit.edu.
⁴ Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. bemead@mit.edu.
⁵ Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA. bemead@mit.edu.
⁶ Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA. jmkarp@bwh.harvard.edu.
⁷ Engineering in Medicine, Department of Medicine, Center for Regenerative Therapeutics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. jmkarp@bwh.harvard.edu.
⁸ Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, USA. jmkarp@bwh.harvard.edu.
⁹ Harvard Stem Cell Institute, Harvard University, Cambridge, MA, USA. jmkarp@bwh.harvard.edu.

PMID: 30917855
PMCID: PMC6437983
DOI: 10.1186/s13059-019-1677-4

Editorial

All models are wrong, but some organoids may be useful

Benjamin E Mead et al. Genome Biol. 2019.

. 2019 Mar 27;20(1):66.

doi: 10.1186/s13059-019-1677-4.

Authors

Benjamin E Mead^{1

2

3

4

5}, Jeffrey M Karp^{6

7

8

9}

Affiliations

¹ Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA. bemead@mit.edu.
² Institute for Medical Engineering and Science (IMES), Massachusetts Institute of Technology, Cambridge, MA, USA. bemead@mit.edu.
³ Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA. bemead@mit.edu.
⁴ Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. bemead@mit.edu.
⁵ Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA. bemead@mit.edu.
⁶ Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA. jmkarp@bwh.harvard.edu.
⁷ Engineering in Medicine, Department of Medicine, Center for Regenerative Therapeutics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. jmkarp@bwh.harvard.edu.
⁸ Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, USA. jmkarp@bwh.harvard.edu.
⁹ Harvard Stem Cell Institute, Harvard University, Cambridge, MA, USA. jmkarp@bwh.harvard.edu.

PMID: 30917855
PMCID: PMC6437983
DOI: 10.1186/s13059-019-1677-4

No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests

JMK has been a paid consultant in the field of regenerative medicine for companies including Stempeutics, Sanofi, Celltex, LifeVaultBio, Takeda, Quthero, and Mesoblast. JMK is also an inventor on a patent that was licensed to Mesoblast. JMK holds equity in Frequency Therapeutics, a company that has licensed IP generated by JMK that may benefit financially if the IP is further validated. The interests of JMK were reviewed and are subject to a management plan overseen by his institutions in accordance with their conflict of interest policies.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

1. Horvath P, Aulner N, Bickle M, Davies AM, Nery ED, Ebner D, et al. Screening out irrelevant cell-based models of disease. Nat Rev Drug Discov. 2016;15:751–769. doi: 10.1038/nrd.2016.175. - DOI - PubMed
1. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32:40–51. doi: 10.1038/nbt.2786. - DOI - PubMed
1. Simian M, Bissell MJ. Organoids: a historical perspective of thinking in three dimensions. J Cell Biol. 2017;216:31–40. doi: 10.1083/jcb.201610056. - DOI - PMC - PubMed
1. Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. Science. 2014;345:1247125. doi: 10.1126/science.1247125. - DOI - PubMed
1. Fatehullah A, Tan SH, Barker N. Organoids as an in vitro model of human development and disease. Nat Cell Biol. 2016;18:246–254. doi: 10.1038/ncb3312. - DOI - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

All models are wrong, but some organoids may be useful

Affiliations

All models are wrong, but some organoids may be useful

Authors

Affiliations

Conflict of interest statement

Competing interests

Publisher’s Note

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources